TwinBeech Capital’s Sarepta Therapeutics SRPT Stock Holding History

TwinBeech Capital’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-280,096	Closed	-$4.79M	–	828
2025 Q2	$4.79M	Buy	280,096 +15,100	+6%	+$644K	0.11%	210
2025 Q1	$16.9M	Buy	+264,996	New	+$27.9M	0.31%	100
2024 Q1	–	Sell	-154,788	Closed	-$14.9M	–	832
2023 Q4	$14.9M	Buy	+154,788	New	+$14.8M	0.24%	124
2023 Q3	–	Sell	-83,201	Closed	-$9.53M	–	884
2023 Q2	$9.53M	Sell	83,201 -57,536	-41%	-$7.42M	0.19%	151
2023 Q1	$19.4M	Buy	140,737 +137,084	+3,753%	+$17.8M	0.39%	72
2022 Q4	$473K	Buy	+3,653	New	+$423K	0.01%	593
2022 Q2	–	Sell	-14,358	Closed	-$1.12M	–	720
2022 Q1	$1.12M	Buy	+14,358	New	+$1.1M	0.05%	306
2021 Q3	–	Sell	-23,155	Closed	-$1.8M	–	750
2021 Q2	$1.8M	Buy	23,155 +13,605	+142%	+$1.03M	0.22%	139
2021 Q1	$712K	Buy	+9,550	New	+$881K	0.1%	244

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

TwinBeech Capital's SRPT Position: Q3 2025 in Review

TwinBeech Capital sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 280,096 shares — an estimated $4.79M sold.

TwinBeech Capital first reported a position in SRPT in Q1 2021 and held it in 9 quarters. The position peaked at $19.4M in Q1 2023. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

TwinBeech Capital reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
TwinBeech Capital sold 280,096 Sarepta Therapeutics shares in Q3 2025, an estimated $4.79M.
TwinBeech Capital first reported a position in Sarepta Therapeutics in Q1 2021 and held it in 9 quarters.
TwinBeech Capital's Sarepta Therapeutics position peaked at $19.4M in Q1 2023.
319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on TwinBeech Capital's 13F filing for Q3 2025, filed 14 Nov 2025.